Enzyme immunoassay for the quantitative determination of Daratumumab (Darzalex®) in serum and plasma.
This kit has been especially developed for the quantitative determination of Daratumumab in serum and plasma samples between the Cmin and Cmax range of concentrations.
Daratumumab Drug Bank Accession Number is DB09331.
Daratumumab is a CD38-directed cytolytic monoclonal antibody that targets CD38+ multiple myeloma cells. Daratumumab is used alone or as an adjunct drug in the treatment of multiple myeloma and light chain amyloidosis. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.
All SHIKARI® ELISA kits are suitable for biosimilar work.
| Required Volume (µl) | 5 |
| Total Time (min) | 100 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 10 |
| Spike Recovery (%) | Between 85-115 |
| Shelf Life (year) | 1 |
| Assay type | Qualitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
Reviews
There are no reviews yet.